Coronavirus 2019-2020 thread (no unsubstantiated rumours!)

taxiya

Brigadier
Registered Member
A Danish Norwegian study has found Astra Zeneca to be generally safe

However I'll ieave it up to forumnites to decide whether 1 in 40000 persons getting a blood clot on the brain is ok

Systematic study of 280,000 vaccinated people aged 18-65
1/However, they identified an increased incidence of blood clots in the veins (venous blood clots), including a slightly increased incidence of blood clots in the veins of the brain, corresponding to one additional such clot per 40,000 vaccine recipients.


These rare blood clots in combination with low platelet counts are referred to as the VITT syndrome. The occurrence of VITT after receiving the AstraZeneca vaccine has led to the removal of the vaccine from the Danish and Norwegian vaccination programmes against COVID-19.

The absolute risk to the individual vaccine recipient is still considered to be low.

Please, Log in or Register to view URLs content!

Haha, yet Norway and Denmark have completely removed AZ vaccine from their vaccination program. Sweden has indefinitely paused AZ to people under 65 years old, the majority of adults.

So the study says "it is safe", but the people says we don't buy the BS, the governments say we don't use it because nobody want it. The risk analysis of the study is another BS. Although the risk of death from AZ is 1/40000, the risk of death from virus using self protection (mask and social distancing) is much lower than 1/40000.

I think the recent incidents of AZ using social media to BSing other vaccines and the "study" in Brazil about SinoVac is a collective effort of AZ to desperately save itself. All of them are coordinated acts.
 

taxiya

Brigadier
Registered Member
Please, Log in or Register to view URLs content!

Interview of Chairman of SinoPharm:

The west does not pursue inactivated vaccine because they are NOT ABLE to. The advantage of inactivated vaccine over any other types are it is more effective against future variant than any other types of vaccine because it uses the full dead body of virus rather than a small piece.
灭活疫苗是一种传统的技术路线,很多人想当然地认为,老技术就是落后的。对此,杨晓明特别强调,这次国药集团中国生物研发的新冠灭活疫苗已经不是“传统的、落后的了,我们是新型灭活疫苗。”

他告诉观察者网:“这一技术路线的各项突破只有中国实现了,比如说毒株筛选技术突破、灭活工艺和评价突破、纯化突破、大规模培养突破等等。西方不做这种新型灭活疫苗,是因为有些方面他们没突破,或者没完全突破。”

杨晓明说:“国产灭活疫苗目前为止仍能有效应对已发现的所有突变毒株,因为灭活疫苗用的是完整的病毒,而不是一个靶点,所以它对全球毒株有广谱的保护性,这是灭活疫苗的突出优势。”
Six key techs that enabled China's speedy development of inactivated vaccine.

First, selection and isolation of desired virus sample in 16 days. This basically defeated the speed advantage of mRNA against new variant.
首先是疫苗生产毒株筛选上的突破,好的病毒灭活疫苗研发始于优良的疫苗生产毒株。传统病毒灭活疫苗制作时,科研人员要花六七个月才能筛选出一个合适的生产种子。但这次,在新冠病毒筛选上,国药冲出了新速度。

杨晓明透露,他们创建了毒株筛选新方法,“只用了16天就筛选到了效力好、产量高、遗传稳定、抗原谱广的疫苗生产病毒种子。”

Second, breakthrough in inactivation process. Safe and adequate to maintain "antigen" characteristic.
第二个是灭活上的突破。灭活工艺的关键就是灭活,把病毒杀死很容易,难就难在要把它杀的恰到好处,刚死,但还可以刺激免疫。

Third, breakthrough in purification in volume. The breakthrough was achieved in 2013 from the IPV vaccine.
杨晓明提到的第三个突破是提纯技术。提纯就去除杂质,把最有效的成份拿出来。他介绍道:“早期的灭活疫苗没有这个技术,不怎么纯化,也没有纯度‘杂质’这个指标,灭活以后稍微调整一下浓度就可以了。2013年以后,我们在研究灭活脊髓灰质炎病毒疫苗的时候,建立了国际上领先水平的灭活疫苗纯化技术。纯化技术的提升使病毒的‘有效抗原’,或者说‘有效的灭活后的完整病毒’能达到99%以上。
“以前要是做到5000万剂,我们全年就不能休息了。但是现在,我们能在高纯度、低杂质的情况下实现规模生产,产能从10亿增加到20亿,然后到30亿。”

Forth, mass production (cultivation of virus). Other countries do not have. Once again from IPV program.
第四个突破是大规模培养。要实现灭活疫苗的量产,首先要有足够多的病毒,然后才能去灭活去提纯。所以,大规模的(病毒)培养也是一项关键技术。

Fifth, packaging.
第五大突破在疫苗的配方,也就是疫苗的成份。

Sixth, bio-safety. SinoPharm has built the production platform including P3 standard in 2017 from the ipv program after 8 years of research. China already have the full set of tech before Covid-19. This is also what I said long time ago that no country has P3 production capability except China.

最后是生物安全问题。杨晓明称,如此大量的病毒培养,在操作过程中首先要保证操作者不能感染,另外也不能放在普通环境里操作和生产,因为一旦泄露就会导致生物安全事故。新冠灭活疫苗的研发必须是在生物安全防护三级(P3)实验室的环境内进行,生产企业也需具备生物安全三级防护标准。

“这次P3生产设施的建设也是一个创新点,”国药集团中国生物的科研人员告诉观察者网,之前国内没有哪个疫苗生产用到P3实验室,国药集团中国生物新冠灭活疫苗生产车间的建成,填补了国内硬件基础设施的空白。

杨晓明说,国药集团中国生物花了8年左右的时间去实现灭活疫苗的技术突破,于2017年建立了新型灭活疫苗这一技术平台。“通过这个平台,我们在脊髓灰质炎灭活疫苗(ipv疫苗)上进行实践并取得了突破,使它的单一品种产能能达到1亿剂。”

“其实,我们的平台和技术早就准备好了。新冠一来,正好撞上了。这就好比要炒菜,但是还没有菜。新冠来了,那就炒一下,炒的过程中又遇到了巨大的需求量。而在解决大规模生产时,我们又取得了一些新的突破。从1亿剂到30亿剂,这种增长要是技术上没突破、没把握的话,是做不了的。”

In summary, in China's perspective, mRNA or any other fancy vaccines have no advantage in dealing Covid-19 and China has a mature and ready production line by 2020. Inactivated vaccine is the natural choice.
 
Last edited:

voyager1

Captain
Registered Member
The advantage of inactivated vaccine over any other types are it is more effective against future variant than any other types of vaccine because it uses the full dead body of virus rather than a small piece.
mRNA or any other fancy vaccines have no advantage in dealing Covid-19
Yeah sorry but this rings some bs bells to me. The advantage of mRNA vaccine is how easily the vaccine can be changed to combat new variants and then easily produced

So while he may be right that inactivated vaccines are more effective against future variants, what happens if a variant emerges that it can bypass the vaccine? How long would the company need to change the vaccine and then scale up production? Months?

While the mRNA tech would just change the vaccine and then produce it the next day
 

siegecrossbow

General
Staff member
Super Moderator
ABC news article about a large cache of intel connected to the covid outbreak in china that the US has collected and still hasnt been fully analysed.

Please, Log in or Register to view URLs content!

I sure hope that once Trump is president again, he could fire those Intelligent agents who sat on their butts for over a year while his election went to hell instead of focusing their efforts on analyzing data that could implicate the evil Chinese in creating COVID in labs and spreading them around the world.
 
Top